BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Fate Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Fate Therapeutics's drugs run\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07570862-5437@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:FT819: Phase 2 readout est. (NCT07570862)
DESCRIPTION:FT819\, phase 2\, Systemic Lupus Erythematosus.\nStudy: A Phase
  2\, Open-Label\, Single-Arm Trial of FT819 in Participants With Lupus Nep
 hritis\nEstimated primary completion: 1 July 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/ft819#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07570862
URL:https://assetmemo.bio/drug/ft819#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
